| DiseaseSite | Abbr Description | RequestedBy | Date Requested |
|---|---|---|---|
| HN | Evaluate practice patterns, dosimetry, toxicity, and clinical outcomes of patients undergoing proton therapy for nasopharyngeal carcinoma. | Stokes, W | 3/31/2022 |
| Eye | Review of outcomes of all patients with ocular melanomas treated at the NM Proton Center, for use in presentation at First International Proton Therapy Symposium, March 2022 | Hartsell, W | 1/10/2022 |
| Abdominal; Pelvic | Evaluate toxicity and efficacy outcomes of patients with abdominal and pelvic cancers who were treated with PT for reirradiation. This is a well-accepted reason for PT yet there are actually quite limited clinical outcomes data. Update to 2019 request. | Chuong, M | 12/21/2021 |
| Lymphoma | To evaluate use of PBS for EFRT among patients with lymphoma. We will study which patients are selected for treatment, technical considerations with using proton therapy, and comparative dosimetry with proton versus photon techniques for EFRT. | Tseng, Y | 9/28/2021 |
| Esophagus | Feasibility, toxicity, tumor control, etc. associated with proton reirradiation for esophageal/GEJ cancer recurrence. Cumulative DVH data to be analyzed using DICOM-RT from initial and reirradiation courses. Updated for longer follow-up duration. | Choi, I | 8/23/2021 |
| Breast | To determine feasibility, toxicity, tumor control, and other relevant clinical outcomes associated with proton reirradiation for breast cancer recurrence. This request is for an updated database query to acquire longer median follow-up/late AEs. | Choi, I | 7/27/2021 |
| Lung; Breast; Prostate | Compile data on outcomes for breast, prostate, and lung cancer - OS, DFS, and Toxicities on patients with 8+ years from proton treatment. OKC only. | Chang, J | 5/19/2021 |
| Pancreas | Outcome review (toxicity / survival) for patients receiving postoperative proton therapy for pancreas cancer | Nichols, R | 3/15/2021 |
| Lung; Esophagus; Lymphoma | To prove the value of and validate Expert-Augmented Machine Learning that we have had piloted and published. Predict the risk of radiation pneumonitis and of esophagitis for patients treated with proton therapy for thoracic malignancies. | Simone, C | 1/28/2021 |
| Anus Anal Canal | Analysis of clinical and dosimetric outcomes among anal squamous cell carcinoma patients treated with definitive chemoradiation using PBT. Exclude if received reirradiation and those who were not treated with definitive intent with at least 45 Gy. | Chuong, M | 12/24/2020 |
| Plasmacytoma | Solitary plasmacytoma/multiple myeloma. This descriptive study seeks to characterize which patients are being selected for proton therapy, outcomes, and toxicity of treatment. A data request was previously submitted in 2017 and this is an update. | Tseng, Y | 10/19/2020 |
| Pancreas | Evaluate the outcomes and toxicity of proton therapy use for pancreatic cancer. Characterize toxicity rates and rates of local and regional control, PFS, and OS. | Chhabra, A | 9/29/2020 |
| Skin | Clinical outcomes, oncologic and reported complication of patients with cutaneous non-melanomatous skin cancer with perineurial invasion following proton radiotherapy. | Holtzman, A | 9/15/2020 |
| HN | Investigate efficacy of unilateral oropharynx proton radiation. Specifically report on local regional control, incidence of contralateral failure and toxicity. | Deraniyagala, R | 7/18/2020 |
| CNS | Outcomes and practice patterns for patients with brain metastases treated wtih proton beam therapy are not well known. The purpose of this study is to analyze outcomes (local control and toxicity) for patients with brain metastases treated with PBT. | Mishra, M | 2/3/2020 |
| CNS | Treatment outcomes for craniopharyngioma and ependymomas. Update to previous request. | Kotecha, R | 1/24/2020 |
| All disease | We will like to have all pediatric data available for Mayo AZ. We will look at clinical outcomes and association with QOL. | Daniels, T | 1/17/2020 |
| HN | Investigate the patterns of utilization, clinical outcomes, and toxicity of patients with mucosal melanoma of the head and neck region treated with proton therapy. Report outcomes in the definitive, post-operative, or salvage re-irradiation setting. | Simone, C | 1/14/2020 |
| Prostate | We will like to have all prostate data available for Mayo AZ. We will look at clinical outcomes and association with QOL. | Vargas, C | 1/8/2020 |
| Lymphoma | Analyze the cohort of both HL and NHL patients registered in the PCG registry to elucidate PBT planning/delivery approaches used to address cardiorespiratory motion when targeting mediastinum and correlating it with toxicity and oncological outcomes | Mohindra, P | 12/31/2019 |
| Gyn | Analyze PCG registry data for patients receiving PBT for gynecological cancers. Outcomes data: acute/late toxicity, cancer and survival status. | Mohindra, P | 12/31/2019 |
| Sarcoma | Ewing and Rhabdomyosarcomas treated with radiation therapy. Primary endpoint: clinical outcomes/acute toxicity. Secondary endpoints: % of pts treated with dose escalated radiotherapy to 64.8 Gy and % treated to non-standard Rt doses. Also IMRT data. | Hall, M | 12/20/2019 |
| Prostate | Overall results of protons for prostate cancer, evaluating survival, biochemical disease free survival, acute and late toxicity. To evaluate all PCG prostate cancer patients except those on active clinical trials. | Hartsell, W | 11/26/2019 |
| HN | The purpose of this project is to review the clinical outcomes and toxicities of patients who received re-irradiation with proton therapy for H&N cancer, with a primary focus on patients with squamous cell carcinoma of the oropharynx. | Kole, A | 11/25/2019 |
| CNS | Adult Craniopharyngioma Outcomes Study- evaluate adults (>21yo) treated with proton radiotherapy for craniopharyngioma. Determine overall survival, disease free survival, local control, and treatment related side effects. | Rutenberg, M | 10/25/2019 |
| Lymphoma | Hodgkin lymphoma and NHL located in the head and neck region treated with PT to assess treatment related outcomes such as local control, regional control, distant control, survival as well as both acute and long term treatment-related toxicities | McGee, L | 10/23/2019 |
| Sarcoma | The PCG registry will be surveyed for all retroperitoneal/pelvic sarcomas who have been treated with preoperative radiation therapy. The primary endpoint is acute GI toxicity observed during treatment. | Hall, M | 10/14/2019 |
| Prostate | Investigate the correlation between overall treatment time and biochemical control, partitioning cohorts primarily by Gleason score. | Hasan, S | 9/2/2019 |
| HN | Investigate the use of post-operative proton therapy for head and neck cancers, inclusive of transoral robotic surgery (TORS) and open surgery, and evaluate associated toxicities and disease outcomes. | Snider, J | 8/26/2019 |
| Lymphoma | Evaluate all lymphoma patients (HL, NHL, relapsed/refractory) that received proton therapy to the mediastinum. | Tseng, Y | 8/8/2019 |
| Salivary | Update the original analysis of salivary gland cancer to include any available photon patients to better show reductions in acute toxicity with PBT, and include a dosimetric analysis using DICOM RT data. | Chuong, M | 7/29/2019 |
| Anus Anal Canal | Update Anal Canal request from Sept. 2018 to include DICOM data. | Chuong, M | 7/8/2019 |
| CNS | Access the toxicities, local control, progression free survival, and overall survival following proton reirradiation for patients with primary brain tumors who had in-field recurrences following an initial course of radiation therapy. | Simone, C | 7/7/2019 |
| Breast | To determine feasibility, toxicity, tumor control, and other relevant clinical outcomes associated with proton reirradiation for breast cancer recurrence. | Choi, I | 7/6/2019 |
| Prostate | Evaluate all our prostate data to look at differences in QOL, toxicity and outcomes for our population for Mayo only. | Vargas, C | 7/2/2019 |
| All disease | An analysis of patterns of PBT utilization across disease sites would be informative to identify areas of particular clinical interest as well as areas with potential clinical benefit that should be further studied. | Chuong, M | 6/20/2019 |
| Pelvic; Abdominal | Evaluate toxicity, tumor control, and overall survival in patients who receive reirradiation to the abdomen/pelvis with proton therapy and photon therapy. | Chuong, M | 6/20/2019 |
| Esophagus | A comprehensive analysis of outcomes in proton vs photon patients (toxicity, tumor control, survival, dosimetry), related to toxicity outcomes of esophageal cancer patients. | Chuong, M | 6/20/2019 |
| Breast | We need all our breast data to look at differences in QOL, toxicity and outcomes for our population, for Mayo only. | Vargas, C | 6/13/2019 |
| CNS | Evaluate patients with craniopharyngioma under the age of 21 years old treated with proton therapy, including demographics, toxicities, outcomes, and treatment replans based on cystic changes to the mass. Northwestern Proton Center. | Hartsell, W | 6/12/2019 |
| Rhabdoid (AT/RT) | Evaluate the PCG registry for patients with atypical teratoid rhabdoid tumor to assess treatment fields (local vs. CSI+local), dose delivered, toxicity, and outcomes. Proton therapy may minimize toxicities in young patients. | Quinn, T | 6/10/2019 |
| Liver | We would like to evaluate the use of proton therapy for hepatocellular carcinoma (liver). Specific interests include: dose escalation, fractionation, outcome data and organ at risk dosimetric data. | Quinn, T | 6/7/2019 |
| All disease | Describe the use of hypofractionated and stereotactic radiotherapy for patients treated with proton therapy to evaluate toxicity outcomes. | Kotecha, R | 6/7/2019 |
| Bile Duct | Evaluate the use of proton therapy for liver cancer (HCC, intrahepatic cholangiocarcinoma). Specific interests include: dose escalation, fractionation, outcome data and organ at risk dosimetric data. | Quinn, T | 6/7/2019 |
| All disease | Evaluate the effect of patients demographics, treatment, and CTCAE on OS for the entire cohort and by disease site; also, association between patient demographics and treatment with patient-rated and clinician-rated toxicity. | Vargas, C | 2/26/2019 |
| All disease | Evaluate overall survival and toxicity following proton or photon irradiation in patients with metastatic disease to bones, liver, lungs, adrenals, brain, lymph nodes, and/or orbit. | Hyde, C | 12/24/2018 |
| Prostate | Review outcomes of proton SBRT for all patients with prostate cancer with the hypothesis that proton SBRT results in improved PROs compared to historical control data. | Rwigema, J | 11/19/2018 |
| All disease | To evaluate the local control and potential toxicity of definitive proton irradiation in cancer patients with oligometastatic spread (1-5 sites). | Hyde, C | 10/29/2018 |
| CNS | Evaluate patients with newly diagnosed high grade glioma treated with proton beam therapy alone. We are looking at outcome and toxicity data. | Vora, S | 10/12/2018 |
| Colorectal | Outcomes/toxicities in patients treated with protons fo rectal cancer with prior history of re-irradiation. | Molitoris, J | 9/5/2018 |
| Anus Anal Canal | Reduced acute toxicity after proton versus photon chemoradiation for anal cancer. | Chuong, M | 9/3/2018 |
| Prostate | Localized prostate cancer treated with curative intent at Mayo Clinic. We will analyze clinical outcomes, toxicities, and QOL. | Vargas, C | 8/20/2018 |
| CNS | Study treatment patterns and clinical outcomes of meningiomas treated with proton beam therapy (PBT). We will focus on base of skull (BOS), recurrent, and grade II/III meningiomas as these groups have a stronger indication for PBT. | Mishra, M | 7/18/2018 |
| Esophagus | Perform analysis on all patients with esophageal tumors looking at clinical efficacy, toxicity, dose/dosimetric, correlations with #1 and #2, reirradiation patient outcomes. | Choi, I | 7/7/2018 |
| Esophagus | Perform analysis on all patients with esophageal tumors looking at clinical efficacy, toxicity, dose/dosimetric, correlations with #1 and #2, reirradiation patient outcomes. | Choi, I | 7/7/2018 |
| All disease | Analyze the number of rescan/replans that were done , and highlight our workflow process on which types of patients we do regular scans, at what intervals, and how many of those resulted in adaptive replans. | Schmidt, S | 5/23/2018 |
| All disease | Analyze the number of rescan/replans that were done , and highlight our workflow process on which types of patients we do regular scans, at what intervals, and how many of those resulted in adaptive replans. | Schmidt, S | 5/23/2018 |
| Prostate | Compare toxicity, QOL, and IPSS of patients treated in GU003 and the PCG registry to different doses. Also use the data of prostate patients in the registry with a potential minimum FU of 3-years. | Vaipiwala, N; Vargas, C | 5/8/2018 |
| Lung | Clinical outcomes following proton therapy for non-small cell lung cancer: description of survival as well as research or predictive factors for adverse Events (with an emphasis on esophagitis). IMRT-only patients will not be included. | Rengan, R | 4/18/2018 |
| Prostate | Evaluate the PCG prostate cancer outcomes for patients treated primarily with proton therapy for prostate cancer, using the same criteria as the Medicare SEER study. | Hartsell, W | 1/28/2018 |
| Lung | Study the outcome of proton beam radiotherapy in pateints w/ locally advanced lung cancer w/ or w/o concurrent chemo and/or previous radiotherapy (Mayo AZ only). | Sio, T | 1/15/2018 |
| Chordoma; Sarcoma | Review outcomes of PBT for skull base chondrosarcomas and chordomas at our institution. Looking at the differences in outcomes for passive vs. pencil beam scanning. Also, outcomes based on extent of surgery (Northwestern Proton (CHI) only). | Sweeney, P | 11/13/2017 |
| HN | PCG Sinonasal database. We only need an updated follow up of the patients that have already been analyzed in this database. | Gamez, M; Patel, S | 11/2/2017 |
| Lung | Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy. | Badiyan, S | 11/1/2017 |
| CNS | Analyze data from patients who have received protons for low-grade gliomas, benign brain tumors and malignant neoplasms (excluding high-grade gliomas). | Kotecha, R | 9/15/2017 |
| HN | Minimal acute toxicity in major salivary gland patients after proton beam therapy. | Chuong, M | 9/15/2017 |
| Breast | Outcomes of breast patients treated with proton therapy. Specifically, outcomes and techniques of Angiosarcoma patients; breast patients receiving re-irradiation to those not; pts receiving salvage protons. | Niska, J; Vargas, C | 9/5/2017 |
| Breast | To evaluate toxicities and clinical outcomes after accelerated partial breast irradiation (APBI) using proton beam therapy (PBT) for early breast cancer. | Thorpe, C; Vargas, C | 9/1/2017 |
| Prostate | Review the dose used, toxicity rates, and outcomes for post-op prostate patients; examine the toxicity and outcome for intact prostate patients treated w/ hypofractionated schedules. | Kaiser, A | 8/28/2017 |
| Myeloma; Plasmacytoma | Outcomes and toxicity among multiple myeloma and solitary plasmacytoma pts treated w/ proton therapy. | Tseng, Y | 8/10/2017 |
| Pancreas | Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry. | Nichols, R | 8/8/2017 |
| Prostate | Compare toxicity and PROs for men receiving prostate radiation alone with both proton modalities (pencil beam scanning vs passive scatter). A secondary aim would be to compare outcomes for men treated with a rectal balloon, rectal spacer, or neither. | Mishra, M | 6/19/2017 |
| CNS | Studying pediatric and adult medullablastoma patients treated with protons. We would report (1) rates, patterns of failure; (2) OS; (3) acute toxicity; (4) late taxicity | Tseng, Y | 6/6/2017 |
| Breast | Acute toxicity analysis of the Partial Breast Irradiation (PBI) Trial (BRE007) | Chang, J | 6/1/2017 |
| All disease | Oral presentation to the National AAMD meeting entitled, "Proton vs Photon Therapy: Which Sites Benefit from Which?" (CHI only) | Schmidt, S | 5/22/2017 |
| Prostate | Analysis of Post Prostatectomy patients looking at PBS protons vs Rapid Arc vs Tomotherapy treatment plans (CHI only). | Chang, J; Schmidt, S | 5/22/2017 |
| Prostate | Evaluating rectal toxicity in prostate patients, looking at 1) incidence with rectal water vs balloon vs hydrogel 2) treatment of rectal bleeding (CHI only) | Hartsell, W | 5/19/2017 |
| CNS | Compile PCG data on Demographics, Sites, Histologies, Treatments, Outcomes - Survival, Control and Toxicities for all Ayptical Teratoid Rhabdoid Tumor patients treated. | Chang, J | 5/13/2017 |
| Thymoma | Retrospective evaluation of patients with thymoma treated at PCG & UFPTI with proton therapy. Plan to review acute and late toxicities and disease specific outcomes among patients treated with thymic malignancies. | Hoppe, B; Mercado, C | 5/9/2017 |
| CNS | Analyzing the data from patients who have received proton beam therapy for high grade glioma to date as a historical control. | Vora, S | 4/29/2017 |
| CNS | Proton therapy patterns of care among pediatric and adult patients with CNS tumors with attention to the demographics and diagnoses/indications of patients receiving CNS-directed proton therapy. | Halasz, L; Tseng, Y | 4/25/2017 |
| Chordoma; Sarcoma | Look at patients with sarcoma and chordoma receiving proton therapy and evaluate treatment outcomes and toxicities. | Simone, C; Verma, V | 3/3/2017 |
| Lung | Evaluate stage III NSCLC patients undergoing definitive treatment with chemo and proton radiation using a machine-learning analytic approach to identify factors predictive for survival and toxicity. | Kunaprayoon, D | 2/23/2017 |
| Prostate | Toxicity, Quality-of-Life Outcomes, and Dosimetric Impact in Phase 3 Trial of Hypofractionated or Standard Fractionated Proton Therapy for Low-Risk Prostate Cancer Patients: PCG GU 002 | Vargas, C | 2/21/2017 |
| Lymphoma | Proton Therapy for Lymphoma: A Multi-Institutional Patterns of Care Study | Mohindra, P | 1/31/2017 |
| Anus Anal Canal; Colorectal | Clinical Outcome & toxicity for uniform scanning proton therapy of rectum & anus (OKC & NJ only). | Zheng, Y | 1/26/2017 |
| Breast | Clinical Outcomes of Breast Proton Radiotherapy | Fega;#23;#Vargas, C | 1/17/2017 |
| HN | Review outcomes for primary & recurrent nasopharynx cancer treated with proton radiation (or reirradiation) - evaluate disease control and survival outcomes and toxicity. | Rutenberg, M | 1/13/2017 |
| Lymphoma | Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Pub Med 2017. | Hoppe, B | 1/1/2017 |
| Prostate | We would like to compare toxicity, QOL (EPIC, SF 12), and IPSS of prostate patients treated in GU002 and the PCG registry to different doses. | Vargas, C | 1/1/2017 |
| Breast | Comparison of acute toxicities between breast patients treated with pencil beam scanning (PBS) technology versus passive scatter; cosmesis and reconstructive results; DVH data | Nichols, E | 12/27/2016 |
| Prostate | An evaluation of prostate volume and proton therapy-related toxicities (CHI only). | Hartsell, W | 12/21/2016 |
| Prostate | We evaluated prostate size versus GU / GI complications in 2014. I would like to update for longer term follow-up. Will use the same group of patients as were studied in 2014 - just need to follow-up since then. | Hartsell, W | 12/21/2016 |
| Prostate | Report on acute toxicities of WK's first ~100 proton prostate patients (baseline, on tx, 3-6 m fu). | Barrow, B | 12/20/2016 |
| Prostate | Report on our institutional outcomes in treating prostate cancer with proton radiation (UW only). | Zeng, J | 12/19/2016 |
| Breast | Acute and Late Toxicity of uniform scanning proton therapy for breast cancer patients (OKC only) | Zheng, Y | 12/15/2016 |
| Lymphoma | Rates of Toxicity and Outcomes after Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma | Tseng, Y | 12/15/2016 |
| GI; Prostate | Minimal Toxicity After Proton Beam Therapy for Prostate and Pelvic Nodal Irradiation: Results from the Proton Collaborative Group REG001-09 trial | Chuong, M | 11/16/2016 |
| Lung | Patient, tumor and treatment characteristics/outcomes, including tumor recurrence, toxicity and death for patients with non-small cell lung cancer receiving re-irradiation with proton therapy who have previously undergone radiation to the thorax. | Badiyan, S | 11/8/2016 |
| Breast | Report on different breast cancer outcomes of patients treated with proton therapy. Local and regional control, distant failure, CSS, OS, timing of radiation, dose and techniques used. Toxicity and review plans for patients with grade 3+ toxicity | Vargas, C | 11/4/2016 |
| Esophagus | Outcomes of esophageal patients treated with proton therapy. Local and regional control, distant failure, CSS, OS, adverse events. Radiation timing, dose, fields. Correlate toxicity with treatment plans. | Sio, T | 11/4/2016 |
| HN | Sinonasal Cancer Patients Treated with Proton Therapy: The Proton Collaborative Group (PCG) Experience | Haro, G; Patel, S | 11/4/2016 |
| All disease | Analyze outcome data of UK subjects treated at OKC only | Chang, A | 11/3/2016 |
| Prostate | Utilization of Machine Learning and Proton Collaborative Group Data to Develop a Model for Predictive Prostate Cancer Proton Radiotherapy Response | Ricks-Santi, L | 10/18/2016 |
| Prostate | Proton therapy for high risk (stage IIB or higher) prostate cancer | Hartsell, W | 8/17/2016 |
| Prostate | Analyze toxicity, QOL, dosimetric end points of GU002. The current analysis will not include the primary end point of the study. | Vargas, C | 7/29/2016 |
| All disease | Analysis of images and movie loops taken of patients treated with protons at Mayo AZ. Info to be shared w/ collatorators at Arizona State University. | Vargas, C | 7/13/2016 |
| CNS | This is an updated request. Determine patterns of failure & outcomes for low-grade glioma after proton therapy. Use PCG registry identify LGG patients who progressed after PT and determine recurrence location relative to original MRI/PT plan. | Wilkinson, J | 7/8/2016 |
| Liver | Report on the PCG Registry liver cancer experience including treatment regimen, disease control, overall survival, toxicity. | Chuong, M | 6/20/2016 |
| Prostate | Evaluating rectal toxicity in prostate patients, especially looking at (1) incidence with rectal water vs. balloon, vs. hydrogel (2) treatment of rectal bleeding | Hartsell, W | 6/16/2016 |
| All disease | Looking at retreat patients treated in 2015 at the NM Chicago Proton Center, regarding different types of cancers that were re-irradiated and looking at the patients' performance status pre and post treatment. | Schmidt, S | 6/13/2016 |
| Esophagus | I would like to present our institutional data on outcomes from esophageal cancer treatment with proton radiation, and present our method of planning for these patients. | Zeng, J | 2/19/2016 |
| Lymphoma | In patients with a new diagnosis of NHL, to report oncological and toxicity outcomes with consolidation PBT usage based on patient demographics, anatomical site, number of involved sites, initial chemotherapy and PET response. | Mohindra, P | 1/30/2016 |
| Lymphoma | Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry. PTCOG 2016. | Hoppe, B | 1/1/2016 |
| Prostate | Intensity modulated proton therapy planning for low-risk prostate cancer based on proton collaborative group (PCG)-GU002-10 (NCT01230866) protocol | Rana, S | 1/1/2016 |
| CNS | Outcomes and toxicity for meningiomas, proton vs photon | Mehta, M | 12/21/2015 |
| Prostate | Comparison of dosimetry and toxicity for prostate patients treated with Hydrogel vs. rectal balloon (002-CHI only) | Conterato, J; McGee, L | 12/16/2015 |
| HN | Long term outcome for Head & Neck cancer treated with protons. | Chang, J | 12/11/2015 |
| Esophagus | Limited Toxicity After Proton Beam Therapy for Esophageal Cancer: Outcomes from the Proton Collaborative Group | Chuong, M | 12/9/2015 |
| Lung | Clinical Outcomes of Patients with Stage II-III Non-Small Cell Lung Cancer (NSCLC) Treated with Proton Beam Therapy (PBT) on the Proton Collaborative Group (PCG) Prospective Registry Trial | Badiyan, S | 12/9/2015 |
| HN | Review of all H&N patients | Chang, J | 8/10/2015 |
| Lung | Review of lung pts at OKC | Zheng, Y | 8/7/2015 |
| All disease | I am proposing a single institution use of the data in the PCG study to assess tolerance of anesthesia with nasal cannula for respiratory support. We would only be looking at patients treated at SCCA proton therapy. | Ermoian, R | 7/5/2015 |
| Breast | Evaluating toxcities outcome in patients receiving thoracic irradiation for | McGee, L | 6/18/2015 |
| Breast | Acute Toxicity Outcomes in Breast Cancer Patients Treated with Adjuvant Proton Therapy | McGee, L | 6/14/2015 |
| CNS | Review of glioma pts to determine recurrence rates | Wilkinson, J | 6/12/2015 |
| CNS | Validate PROMIS measures in the pediatric brain tumor population. Clinical investigators can then monitor the long-term effects of treatment and compare the effectiveness of different treatments, ultimately resulting in improved care. | Lai, J | 4/14/2015 |
| Lung | Review all of the lung patients enrolled in the registry to determine why they were not eligible for the LUN005 study. The bigger picture here is to note how current clinical trials are perhaps overly exclusive when it comes to this patient population. | Hoppe, B | 4/2/2015 |
| Lung | Review of enrolled lung pts to determine cause of LUN005 underenrollment | Dunn, M; Hoppe, B; Simone, C | 4/2/2015 |
| Prostate | Review of prostate pts greater than 4 years post tx | Vargas, C | 4/1/2015 |
| Prostate | Clinical evaluation of prostate cancer patients with metallic hip prosthesis using anterior-oblique and lateral proton beams | Rana, S | 3/23/2015 |
| Prostate | Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles | Rana, S | 3/23/2015 |
| Prostate | Investigate the correlation between clinical results, dosimetric results and radiobiological results for prostate cancer cases at ProCure OKC. | Rana, S | 3/23/2015 |
| Breast | A Clinical Outcomes after Proton Partial Breast Radiotherapy for Early Stage- Hormone Receptor Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial | Chang, A | 2/17/2015 |
| Pancreas | Review toxicity and outcomes for patients receiving proton therapy for pancreatic cancer in the PCG Registry. | Nichols, R | 2/13/2015 |
| Prostate | Prostate cancer patients involving metallic hip prosthesis. (1) Investigate the correlation between clinical results and dose-volume histogram (DVH) parameters. (2) Investigate how radiolobiological results are related to the clinical results. | Rana, S | 1/20/2015 |
| All disease | A review of all potential registry patients who were not enrolled to determine causes of non-enrollment. Reasons for non-enrollment will be categorized and any trends indicating potential selection bias will be noted. | Dunn, M | 1/19/2015 |
| Prostate | toxicity in post prostetectomy pts. CHI only | McGee, L | 12/17/2014 |
| Prostate | We will be evaluating the quality of life surveys of the men treated with prostate cancer with proton therapy who are on the PCG registry. Specifically, comparison of urinary and bowel function prior to treatment, with those after treatment. | Chang, A | 12/12/2014 |
| Prostate | Review acute and late toxiciites for patients treated with protons for prostate cancer using either a rectal balloon or free water | Risberg, E | 12/9/2014 |
| CNS | The primary objective is to look at incidences of grade 3 or higher radiation necrosis of the brainstem in patients <18 years of age who completed treatment on or before July 1, 2014. | Hartsell, W | 9/1/2014 |
| Prostate | Hypofractionated vs. standard fractionated proton beam therapy for low risk prostate cancer: Interim results of a randomized trial- PCG GU002. PTCOG 2015. | Vargas, C | 6/23/2014 |
| Breast | Review of acute toxicities in breast cancer patients treated with IBL | McGee, L | 5/30/2014 |
| CNS | Analysis of progression patterns and rates following proton therapy for low grade glioma | Gondi, V | 5/27/2014 |
| CNS | A review of all ATRT patients | Chang, J | 2/20/2014 |
| All disease | Validation of PROMIS measures using regsitry data for patients enrolled in both trials | Lai, J | 1/30/2014 |
| Chordoma; Prostate | Review of treatment methods such as uniform scanning and pencil beam scanning, Comparison of patients treatment times and plans for prostate and chordoma patients. (002-CHI Only) | DeLongpre, R | 1/21/2014 |
| Hepatobiliary | Review outcomes efficacy and toxicity (acute and late) of patients with unresectable cholangiocarcinomas. | McGee, L | 1/17/2014 |
| GI; Prostate; CNS | Evaluating GI/GU toxicities in spinal cord treatment patients that are not receiving chemotherapy (002-CHI Only) | Jefferis, J | 1/17/2014 |
| All disease | Frequency and severity of dermatitis in uniform scanning vs. PBS | Rendall, R | 1/13/2014 |
| Prostate | Review of urinary and rectal symptoms for prostate patients. | Rendall, R | 1/3/2014 |
| Lung; Prostate | Dosimetric study of PT planning comparison w IMRT and VMAT. Includes CT data involving 1) high risk prostate cancer cases 2) 4 prostate cases involving hip prosthesis and 3) 1 bilateral lung cancer case. | Rana, S | 12/30/2013 |
| HN | We would like to look at Head & Neck patients that had PEG tubes placed during proton treatment. Also, we would like to look at adverse events before & after PEG placement. | Woods, C | 12/24/2013 |
| GI; Prostate | To review EPIC toxicity data (GU, GI, erectile function, overall QOL) for prostate patients treated at our center and to assess if outcomes differ by prostate size. | Goenka, A | 12/20/2013 |
| Prostate | Review long term outcomes and toxicity of patients receiving proton therapy for prostate cancer; review PSA decline and nadir times following protons | Hartsell, W | 12/19/2013 |
| CNS | Developing treatment strategies for craniospinal irradiation looking at immobilzation techniques and pencil beam scanning | Keole, S | 12/18/2013 |
| Chordoma; Sarcoma | PT for chordomas and chondrosarcomas of skull base and axial skeleton. Tu control, survival and side effects | Hug, E | 12/17/2013 |
| Prostate | Comparision of self-report (QoL) depression scores pre and post treatment among prostate cancer patients | Dunn, M | 12/6/2013 |
| Eye | 3d planning of occular melanoma cases | Hartsell, W | 11/7/2013 |
| Breast | Comprehensive breast planning - case studies | Schmidt, S | 10/25/2013 |
| All disease | Develop a near-real time outcomes monitoring system. The purpose of this data request is to validate a proposed approach to automatically identify treatment specific patient cohorts and displaying toxicity data as a time series. | Christodoeleas, J | 9/26/2013 |
| Lung | Giving a local talk about treating lung patients at the OKC center | Prabhu, K | 9/9/2013 |
| Prostate | Retrospective review of outcomes and toxicity for patients with prostate cancer treated with anterior oriented beams | Couran, J | 8/29/2013 |
| Prostate | We would like to review the initial outcomes for prostate cancer for men who are >2 years from end of treatment (so end of treatment Aug 2011 or earlier) - I estimate 200-250 | Keole, S | 8/25/2013 |
| Lung | We would like to review the initial outcomes for lung cancer treated with protons. Control, surival and toxicity. Also need for replanning during RT. | Keole, S | 8/25/2013 |
| All disease | Use of data for pulling grade 3 and higher events for M&M conferences being held qtrly at Procure. | Hug, E | 7/16/2013 |
| All disease; Prostate | 2 Requests in one. Use the same data for published proton TLD paper for getting the planning parameters for proton IMPT prostate planning. | Hug, E | 6/6/2013 |
| CSI | CSI BST Eval using PBS | Siddiqui, M | 2/13/2013 |
| Pancreas | Pancreas sparing during CSI | Gans, S | 2/13/2013 |
| Breast | Simulation, Tx planning and Tx delivery of the breast/chest wall using uniform scanning proton beam therapy | Schmidt, S | 2/12/2013 |
| Lung | Use 10 patients lung clinical data to collaborate on project with UPenn retreatment protocol patients. Chicago only. | Hartsell, W | 2/6/2013 |
| Eye | Presentation of occular tumors treated with PT for ASRT | Tatum, T | 1/25/2013 |
| Eye | Ciliary Body Sparing for Ocular Melanoma with 3D Planning | Hartsell, S | 1/14/2013 |
| CNS | Medulloblastoma PT tx may reduce risk of long term IDDM | Gondi, V | 12/18/2012 |
| Prostate | Basically a follow-up to Keole's 2012 ASTRO presentation. Prostate ca pts with at least 1 year follow up looking at dx perimeters (PSA, Gleason, Stage), demographics (age, race), QOL, pre and post PSA | Hartsell, W | 12/18/2012 |
| Prostate | (1) Comparison of standard 8 week PT outcomes with a more cost-effective and potentially more effective hypofractionated proton therapy (6 week course). (2) Comparison of PT QoL outcomes with intensity-modulated radiotherapy (IMRT). | Hartsell, W; Hoppe, B | 12/11/2012 |
| Prostate | Overall data to be able to present number of patients, risk factors (PSA, Gleasons score), demographics (age, race), acute toxicity, QoL; general info to counsel patients | Cersonsky, N | 11/28/2012 |
| CNS | Review toxicities & control rates for skull base tumors, menengiomas & cavernous sinus tumors | Larson, G | 9/10/2012 |
| HN | Planning of techniques of proton boost for treating oropharnyx tumors of head & neck cancers. | Hsi, W | 3/1/2012 |
| CNS | Craniopharyngioma outcomes. 15 patients | Keole, S | 2/15/2012 |
| Lymphoma | Lymphoma, thynoma, thoracic malignancy planning study of IMRT vs PBRT | Chang, J | 2/14/2012 |
| Prostate | Evaluation of up to 10 patients who were simulated and contoured for the GU002-10 trial. Will evaluate the differences in amounts of bone marrow irradiation comparing protons to IMRT plans when treating to 79.2 Gy in 44 fractions | Yajnik, S | 2/9/2012 |
| Prostate | Poster for AAMD describing the technique for the treatment of high risk prostate w pelvic nodes using a fixed horizontal proton beam line | Schenkenfelder, P | 2/8/2012 |
| Breast | Comparative study evaluating the use of uniform scanning PBT, helical photon therapy and electronic compensation using photon therapy for treating a pt with left sided chest wall, supraclavicular and internal mammary lymph nodal treatment volumes | Schmidt, S | 2/7/2012 |
| CNS | Examining uniform scanning PBT combined with 6 Mev EBT to deliver 50 CGE with a SIB for pediatric orbital rhabdomyosarcoma | Schmidt, S | 2/7/2012 |
| All disease; Prostate | Contrast endorectal balloon in post prostatectomy proton therapy alignment. | Rendall, R | 1/30/2012 |
| Prostate | Initial Outcomes for Men with Prostate Cancer treated with Uniform Scanning Proton Therapy | Keole, S | 10/20/2011 |
| All disease | Tx plan comparison book. | Blair, A | 5/25/2011 |
| Prostate | Initial Toxicities of Prostate Cancer Patients Treated with Active Beam Scanning Proton Therapy | Keole, S | 3/15/2011 |
| CSI | Data from 3 patients from Chicago and 3 patients from OKC. They were all CSI patients treated in the prone position to look at dosimetry planning, DVHs, treatment setup and times/efficiency. This is a proof in principle study looking at IBL use for CSI. | Chang, J | 3/1/2011 |
| Hepatobiliary | Evaluate efficacy and toxicity outcomes for patients with HCC. | Chuong, M | 6/3/2022 |
| All disease | Review of hypofractionated and stereotactic radiation for liver metastases treated with proton beam therapy. | Rao, A | 5/25/2022 |
| Thymoma | Clinical outcomes of patients with thymic malignancies treated with proton therapy (last reviewed early 2017, now with dosimetric/DVH data) specifically looking at disease/survival endpoints, toxicity, patterns of failure, and dosimetry correlates | Tian, S | 4/25/2022 |
| Sarcoma | Ewing and Rhabdomyosarcomas treated with RT. Primary endpoint is acute toxicity observed during tx. Secondary endpoints include % of patients treated with dose escalated radiotherapy beyond conventional doses and % treated to non-standard radiation doses | Hall, M | 12/8/2022 |
| All disease | There are increasing indications for para-aortic RT in patients with regional and distant lymph node dissemination of cancer. RT to the para-aortic lymph nodes is associated with increased risk of toxicity due to dose to the liver, bowel etc. | Shen, X | 5/31/2023 |
| Prostate | I would like to evaluate the GI/GU toxicity rate for patients receiving proton therapy to pelvic nodes compared to those receiving prostate only radiation. | Hasan, S | 7/13/2023 |
| CNS Adult | In-field recurrences for primary brain tumors are common, but current treatment options for recurrent patients are limited. Reirradiation may provide the most durable treatment option, but its side effect profile is poorly defined. | Press, R | 2/16/2024 |
| Gynecological | Radiotherapy is used for a variety of indications in gynecological malignancies including as the primary modality in locally advanced cervix cancer, and as primary or adjuvant therapy in many uterine, vaginal, and vulvar cancers. | Weiss, Y | 1/10/2024 |
| HN | Recurrent head and neck cancer patients treated with proton therapy for re-irradiation. Retrospectively evaluate oncologic outcomes s/p proton reirradiation in respect to local control, metastasis-free survival, disease-free survival and overall QOL. | McGee, L | 12/29/2023 |
| HN | This will be a retrospective analysis of adenoid cystic carcinoma patients treated with definitive or postoperative curative-intent proton therapy. The goal is to assess outcomes including local control, disease specific survival | McGee, L | 11/13/2023 |
| Testicular | To report a pooled multicenter retrospective review of outcomes of PBT for testicular seminoma treated at PCG institutions in patients with Stage I to II disease. If available, we would like to review both disease outcomes and toxicity endpoints. | Liao, J | 11/1/2023 |
| Pancreas | The project aims to evaluate the safety and efficacy of proton beam radiation therapy in treating borderline resectable and locally advanced pancreatic cancer. We will focus on analyzing practice patterns, assessing rates of disease control | Chawla, A | 3/12/2024 |
| Registry | A descriptive analysis of the PCG Registry from its inception to current day to illustrate changes over time in cancer types treated with PBT, their relationship to the ASTRO Model Policy Groups, and patient factors associated with receipt of PBT. | Chuong, M | 1/10/2024 |
| Lung | The goal of this study is to better characterize the acute tolerability and side effect profile of proton therapy for the management of thoracic cancers in patients age 70 years and older. | Shaverdian, N | 05/26/2024 |
| Lung | We seek to review all early-stage non-small cell lung cancer cases in the registry treated definitively with up to 15 fractions of proton therapy. Within this group of patients, we may perform subgroup analyses on more specific scenarios. | Ferris, M | 05/13/2024 |
PROTON COLLABORATIVE GROUP
CORPORATE OFFICE
4320 Winfield Road, Suite 200
Warrenville, IL 60555
Copyright © 2025 · PROTON COLLABORATIVE GROUP · All Rights Reserved · Designed & Developed By Symboliq Media